{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:20:10Z","timestamp":1794738010553,"version":"4.9.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed\/refractory B-cell lymphomas (BCLs) who received Br-RT followed by CAR-T from 2018 to 2020 across 10 institutions. Br-RT toxicities were graded per Common Terminology Criteria for Adverse Events version 5.0, and cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) per American Society for Transplantation and Cellular Therapy Consensus Guidelines. One hundred seventy-two patients (168 large BCL) received Br-RT before axicabtagene ciloleucel (73%), tisagenlecleucel (24%), or brexucabtagene autoleucel (2%). At leukapheresis, most patients (74%) had advanced-stage disease and 39% had bulky disease measuring \u226510cm. Comprehensive Br-RT was administered to 39% and bridging systemic therapy to 35%. Among all patients, grade \u22653 Br-RT toxicity occurred in 2% (1 grade 5 toxicity), grade \u22653 CRS in 9%, and grade \u22653 ICANS in 24%. Median follow-up was 31.3 months. Two-year progression-free survival (PFS) and overall survival (OS) were 38% and 53%, respectively. On multivariable analysis, comprehensive Br-RT was associated with superior PFS (hazard ratio [HR], 0.38; P &amp;lt; .001) and OS (HR, 0.48; P = .011). Patients with lactate dehydrogenase (LDH) normalization after Br-RT (high pre-Br-RT LDH, normal post-Br-RT LDH) had superior PFS and OS compared with those with high post-Br-RT LDH and similar PFS and OS compared with those with normal baseline LDH. In this particularly high-risk cohort, Br-RT before CAR-T demonstrates an acceptable toxicity profile with favorable clinical outcomes compared with historical controls. Comprehensive Br-RT and LDH normalization after Br-RT may be associated with superior PFS and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015855","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:11:58Z","timestamp":1744211518000},"page":"3293-3303","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study"],"prefix":"10.1182","volume":"9","author":[{"given":"Nikhil","family":"Yegya-Raman","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Plastaras","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Wright","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"},{"name":"2Radiation Oncology Associates, Burlington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Chelius","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0610-8809","authenticated-orcid":false,"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Baron","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harper","family":"Hubbeling","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"},{"name":"4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-4347","authenticated-orcid":false,"given":"Austin J.","family":"Sim","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL"},{"name":"6Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-0668","authenticated-orcid":false,"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL"},{"name":"7Department of Therapeutic Radiology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"8Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5915","authenticated-orcid":false,"given":"Brandon","family":"Imber","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fregonese","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-3415","authenticated-orcid":false,"given":"Colton","family":"Ladbury","sequence":"additional","affiliation":[{"name":"9Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Dandapani","sequence":"additional","affiliation":[{"name":"9Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian R.","family":"Gunther","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny Q.","family":"Fang","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-842X","authenticated-orcid":false,"given":"Susan Y.","family":"Wu","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Yang","sequence":"additional","affiliation":[{"name":"11Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Chew","sequence":"additional","affiliation":[{"name":"12Department of Radiation Oncology, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-9357","authenticated-orcid":false,"given":"Steve","family":"Braunstein","sequence":"additional","affiliation":[{"name":"12Department of Radiation Oncology, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-0340","authenticated-orcid":false,"given":"Sumi","family":"Sinha","sequence":"additional","affiliation":[{"name":"12Department of Radiation Oncology, University of California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-7547","authenticated-orcid":false,"given":"Nathan M.","family":"Delinger","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sun","sequence":"additional","affiliation":[{"name":"14Department of Radiation Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Terezakis","sequence":"additional","affiliation":[{"name":"14Department of Radiation Oncology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gukan","family":"Sakthivel","sequence":"additional","affiliation":[{"name":"15Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[{"name":"15Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-5060","authenticated-orcid":false,"given":"Amit K.","family":"Chowdhry","sequence":"additional","affiliation":[{"name":"15Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"16Department of Medicine, Hematology\/Oncology, Wilmot Cancer Institute, University of Rochester School of Medicine, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-1152","authenticated-orcid":false,"given":"Skyler","family":"Burke","sequence":"additional","affiliation":[{"name":"17Department of Radiation Oncology, University of Washington\/Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda D.","family":"Tseng","sequence":"additional","affiliation":[{"name":"17Department of Radiation Oncology, University of Washington\/Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-5086","authenticated-orcid":false,"given":"Michael J.","family":"LaRiviere","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Maity","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA"},{"name":"18Department of Radiation Oncology, Huntsman Cancer Institute and University of Utah Health, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"19Hematology\/Oncology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"20Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-1625","authenticated-orcid":false,"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"19Hematology\/Oncology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"20Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3320","authenticated-orcid":false,"given":"Nicholas B.","family":"Figura","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"10254","key":"2025070811321249000_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2025070811321249000_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2025070811321249000_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2025070811321249000_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl J Med"},{"key":"2025070811321249000_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"issue":"5","key":"2025070811321249000_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas following chimeric antigen receptor (CAR) T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2025070811321249000_bib7","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1182\/bloodadvances.2024013647","article-title":"Outcomes of r\/r B-cell NHL patients with limited (&lt;5 Sites) pre-CART disease bridged with or without radiotherapy","volume":"8","author":"Saifi","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2025070811321249000_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2022.12.017","article-title":"Don't put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"116","author":"Saifi","year":"2023","journal-title":"Int J Radiat Onco Biol Phys"},{"issue":"4","key":"2025070811321249000_bib9","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2025070811321249000_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2025070811321249000_bib11","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2025070811321249000_bib12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2025070811321249000_bib13","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ajh.27409","article-title":"Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"99","author":"Ababneh","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"2025070811321249000_bib14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"2025070811321249000_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","article-title":"Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium","volume":"8","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2025070811321249000_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamaoncol.2024.1113","article-title":"Comprehensive bridging radiotherapy for limited pre-CART non-Hodgkin lymphoma","volume":"10","author":"Saifi","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7","key":"2025070811321249000_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"27","key":"2025070811321249000_bib18","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025070811321249000_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2025070811321249000_bib20","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025070811321249000_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"2025070811321249000_bib22","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025070811321249000_bib23","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.3324\/haematol.2023.283311","article-title":"Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma","volume":"108","author":"Saifi","year":"2023","journal-title":"Haematologica"},{"issue":"24","key":"2025070811321249000_bib24","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv"},{"issue":"22","key":"2025070811321249000_bib25","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3293\/2382936\/blooda_adv-2025-015855-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3293\/2382936\/blooda_adv-2025-015855-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:32:21Z","timestamp":1751974341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3293\/536662\/Bridging-radiotherapy-before-chimeric-antigen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015855","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,6,27]]}}}